ABLYNX SIGNS EXCLUSIVE LICENSE AGREEMENT WITH EDDINGPHARM TO DEVELOP AND COMMERCIALISE ITS ANTI-TNFa NANOBODY IN GREATER CHINA - Seite 3

More information can be found on www.eddingpharm.com

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t:   [phone]
m: [phone] /
     [phone]
e:  [e-mail]

Marieke Vermeersch
Associate Director Investor Relations
t:   [phone]
m: [phone]
e:  [e-mail]
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   [phone]
e:  [e-mail]

Eddingpharm:
United States:
Dr XiaomingZou
Chief Business Officer
t: [phone]
e: [e-mail]

Shanghai:
Ms Eva Bao
Public Relations
t: [phone]
e: [e-mail]

pdf format of the press release

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1852452